Hepcidin levels and their determinants in different types of myelodysplastic syndromes

PLoS ONE

Volumn 6, Issue 8, 2011, Pages

  Santini, Valeria ^a   Girelli, Domenico ^b   Sanna, Alessandro ^a   Martinelli, Nicola ^b   Duca, Lorena ^c   Campostrini, Natascia ^b   Cortelezzi, Agostino ^c   Corbella, Michela ^b   Bosi, Alberto ^a   Reda, Gianluigi ^c   Olivieri, Oliviero ^b   Cappellini, Maria Domenica ^c  

^a UNIVERSITY OF FLORENCE   (Italy)

^b UNIVERSITY OF VERONA   (Italy)

^c UNIVERSITY OF MILAN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; FERRITIN; GROWTH DIFFERENTIATION FACTOR 15; HEPCIDIN; TRANSFERRIN; ANTIMICROBIAL CATIONIC PEPTIDE; IRON;

AGED; ARTICLE; BLOOD SAMPLING; BLOOD TRANSFUSION; CHRONIC MYELOMONOCYTIC LEUKEMIA; CONTROLLED STUDY; DIAGNOSTIC VALUE; FEMALE; FERRITIN BLOOD LEVEL; HOMEOSTASIS; HORMONAL REGULATION; HORMONE BLOOD LEVEL; HORMONE DETERMINATION; HUMAN; IRON METABOLISM; IRON OVERLOAD; MALE; MASS SPECTROMETRY; MYELODYSPLASTIC SYNDROME; PREDICTION; REFRACTORY ANEMIA WITH EXCESS BLASTS; REFRACTORY ANEMIA WITH RINGED SIDEROBLASTS; UPREGULATION; VALIDATION PROCESS; BIOLOGICAL MODEL; BLOOD; CASE CONTROL STUDY; CLASSIFICATION; REFERENCE VALUE; STATISTICAL MODEL; WORLD HEALTH ORGANIZATION;

AGED; ANTIMICROBIAL CATIONIC PEPTIDES; BLOOD TRANSFUSION; CASE-CONTROL STUDIES; FEMALE; FERRITINS; HOMEOSTASIS; HUMANS; IRON; LINEAR MODELS; MALE; MODELS, BIOLOGICAL; MYELODYSPLASTIC SYNDROMES; REFERENCE VALUES; WORLD HEALTH ORGANIZATION;

EID: 80051841329     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0023109     Document Type: Article

References (49)

1. Tefferi A, Vardiman JV, (2009) Myelodysplastic syndromes. N Engl J Med 361: 1872-1885.
2. Fenaux P, Rose C, (2009) Impact of iron overload in myelodysplastic syndromes. Blood Rev 23 (Suppl 1): S15-19.
3. Malcovati L, Porta MG, Pascutto C, Invernizzi R, Boni M, et al. (2005) Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: a basis for clinical decision making. J Clin Oncol 23: 7594-7603.
4. Cortelezzi A, Cattaneo C, Cristiani S, Duca L, Sarina B, et al. (2000) Non-transferrin-bound iron in myelodysplastic syndromes: a marker of ineffective erythropoiesis? Hematol J 1: 153-158.
5. Ganz T, Nemeth E, (2011) Hepcidin and disorders of iron metabolism. Annu Rev Med 62: 347-360.
6. Pullarkat V, (2009) Objectives of iron chelation therapy in myelodysplastic syndromes: more than meets the eye? Blood 114: 5251-5255.
7. Donovan A, Lima CA, Pinkus JL, Pinkus GS, Zon LI, et al. (2005) The iron exporter ferroportin/Slc40a1 is essential for iron homeostasis. Cell Metab 1: 191-200.
8. Nemeth E, Tuttle MS, Powelson J, Vaughn MB, Donovan A, et al. (2004) Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization. Science 306: 2090-2093.
9. Hentze MW, Muckenthaler MU, Galy B, Camaschella C, (2010) Two to tango: regulation of Mammalian iron metabolism. Cell 142: 24-38.
10. Tanno T, Bhanu NV, Oneal PA, Goh SH, Staker P, et al. (2007) High levels of GDF15 in thalassemia suppress expression of the iron regulatory protein hepcidin. Nat Med 13: 1096-1101.
11. Tanno T, Noel P, Miller JL, (2010) Growth differentiation factor 15 in erythroid health and disease. Curr Opin Hematol 17: 184-190.
12. Kroot JJ, Kemna EH, Bansal SS, Busbridge M, Campostrini N, et al. (2009) Results of the first international round robin for the quantification of urinary and plasma hepcidin assays: need for standardization. Haematologica 94: 1748-1752.
13. Castagna A, Campostrini N, Zaninotto F, Girelli D, (2010) Hepcidin assay in serum by SELDI-TOF-MS and other approaches. J Proteomics 73: 527-536.
14. Winder A, Lefkowitz R, Ghoti H, Leiba M, Ganz T, et al. (2008) Urinary hepcidin excretion in patients with myelodysplastic syndrome and myelofibrosis. Br J Haematol 142: 669-671.
15. Murphy PT, Mitra S, Gleeson M, Desmond R, Swinkels DW, (2009) Urinary hepcidin excretion in patients with low grade myelodysplastic syndrome. Br J Haematol 144: 451-452.
16. Cheson BD, Greenberg PL, Bennett JM, Lowenberg B, Wijermans PW, et al. (2006) Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. Blood 108: 419-425.
17. Vardiman JW, Harris NL, Brunning RD, (2002) The World Health Organization (WHO) classification of the myeloid neoplasms. Blood 100: 2292-2302.
18. Bozzini C, Campostrini N, Trombini P, Nemeth E, Castagna A, et al. (2008) Measurement of urinary hepcidin levels by SELDI-TOF-MS in HFE-hemochromatosis. Blood Cells Mol Dis 40: 347-352.
19. Swinkels DW, Girelli D, Laarakkers C, Kroot J, Campostrini N, et al. (2008) Advances in quantitative hepcidin measurements by time-of-flight mass spectrometry. PLoS One 3: e2706.
20. Campostrini N, Castagna A, Zaninotto F, Bedogna V, Tessitore N, et al. (2010) Evaluation of hepcidin isoforms in hemodialysis patients by a proteomic approach based on SELDI-TOF-MS. J Biomed Biotechnol 2010: 329646.
21. Nemeth E, Ganz T, (2006) Hepcidin and iron-loading anemias. Haematologica 91: 727-732.
22. Porter JB, Rafique R, Srichairatanakool S, Davis BA, Shah FT, et al. (2005) Recent insights into interactions of deferoxamine with cellular and plasma iron pools: Implications for clinical use. Ann N Y Acad Sci 1054: 155-168.
23. Gosriwatana I, Loreal O, Lu S, Brissot P, Porter J, et al. (1999) Quantification of non-transferrin-bound iron in the presence of unsaturated transferrin. Anal Biochem 273: 212-220.
24. Traglia M, Girelli D, Biino G, Campostrini N, Corbella M, et al. (2011) The association of HFE and TMPRSS6 genetic variants to iron and erythrocyte parameters is only in part dependent from serum hepcidin levels. J Med Genet In press.
25. Malcovati L, Della Porta MG, Cazzola M, (2006) Predicting survival and leukemic evolution in patients with myelodysplastic syndrome. Haematologica 91: 1588-1590.
26. Buja LM, Roberts WC, (1971) Iron in the heart: etiology and clinical significance. Am J Med 51: 209-221.
27. Gattermann N, (2007) Guidelines on iron chelation therapy in patients with myelodysplastic syndromes and transfusional iron overload. Leuk Res 31: S10-15.
28. Bennett JM, (2008) Consensus statement on iron overload in myelodysplastic syndromes. Am J Hematol 83: 858-861.
29. Rose C, Brechignac S, Vassilief D, Pascal L, Stamatoullas A, et al. (2010) Does iron chelation therapy improve survival in regularly transfused lower risk MDS patients? A multicenter study by the GFM (Groupe Francophone des Myélodysplasies). Leuk Res 34: 864-870.
30. Piperno A, (1998) Classification and diagnosis of iron overload. Haematologica 83: 447-455.
31. Breda L, Ghoti H, Rivella S, Rechavi G, Cabantchik I, et al. (2007) Expression of genes regulating iron metabolism in hepatocyte cell-line HepG2 induced by sera from MDS patients. Blood 110: 4612a.
32. Finch CA, Huebers H, (1982) Perspectives in iron metabolism. N Engl J Med 306: 1520-1528.
33. Cazzola M, Della Porta MG, Malcovati L, (2008) Clinical relevance of anemia and transfusion iron overload in myelodysplastic syndromes. Hematology Am Soc Hematol Educ Program pp. 166-175.
34. Mariani R, Pelucchi S, Pozzi M, Paolini V, Piperno A, (2008) Reduced expression of hepcidin in patients with myelodysplastic syndrome and myelofibrosis: the causes might be more heterogeneous than in thalassaemia. Br J Haematol 143: 746-747.
35. Bootcov MR, Bauskin AR, Valenzuela SM, Moore AG, Bansal M, et al. (1997) MIC-1, a novel macrophage inhibitory cytokine, is a divergent member of the TGF-β superfamily. Proc Natl Acad Sci USA 94: 11514-11519.
36. Ramirez JM, Schaad O, Durual S, Cossali D, Docquier M, et al. (2009) Growth differentiation factor 15 production is necessary for normal erythroid differentiation and is increased in refractory anaemia with ring-sideroblasts. Br J Haematol 144: 251-262.
37. Kempf T, Sinning JM, Quint A, Bickel C, Sinning C, et al. (2009) Growth-differentiation factor-15 for risk stratification in patients with stable and unstable coronary heart disease: results from the AtheroGene study. Circ Cardiovasc Genet 2: 286-292.
38. Zaidi SH, Huang Q, Momen A, Riazi A, Husain M, (2010) Growth differentiation factor 5 regulates cardiac repair after myocardial infarction. J Am Coll Cardiol 55: 135-143.
39. Tanno T, Porayette P, Sripichai O, Noh SJ, Byrnes C, et al. (2009) Identification of TWSG1 as a second novel erythroid regulator of hepcidin expression in murine and human cells. Blood 114: 181-186.
40. Arosio P, Ingrassia R, Cavadini P, (2009) Ferritins: a family of molecules for iron storage, antioxidation and more. Biochim Biophys Acta 1790: 589-599.
41. Gandon Y, Olivié D, Guyader D, Aubé C, Oberti F, et al. (2004) Non-invasive assessment of hepatic iron stores by MRI. Lancet 363: 357-362.
42. St Pierre TG, Clark PR, Chua-anusorn W, Fleming AJ, Jeffrey GP, et al. (2005) Noninvasive measurement and imaging of liver iron concentrations using proton magnetic resonance. Blood 105: 855-861.
43. Armand P, Kim HT, Rhodes J, Sainvil MM, Cutler C, et al. (2011) Iron Overload in Patients with Acute Leukemia or MDS Undergoing Myeloablative Stem Cell Transplantation. Biol Blood Marrow Transplant 17: 852-860.
44. Valenti L, Girelli D, Valenti GF, Castagna A, Como G, et al. (2009) HFE mutations modulate the effect of iron stores and inflammation on serum hepcidin-25 in chronic hemodialysis patients. Clin J Am Soc Nephrol 4: 1331-1337.
45. Girelli D, Trombini P, Busti F, Campostrini N, Sandri M, et al. (2010) A time course of hepcidin response to iron challenge in HFE and TfR2 Haemochromatosis patients. Haematologica 96: 500-506.
46. Nemeth E, Valore EV, Territo M, Schiller G, Lichtenstein A, et al. (2003) Hepcidin, a putative mediator of anemia of inflammation, is a type II acute-phase protein. Blood 101: 2461-2463.
47. Wessling-Resnick M, (2010) Iron homeostasis and the inflammatory response. Annu Rev Nutr 30: 105-122.
48. Sasu BJ, Cooke KS, Arvedson TL, Plewa C, Ellison AR, et al. (2010) Antihepcidin antibody treatment modulates iron metabolism and is effective in a mouse model of inflammation-induced anemia. Blood 115: 3616-3624.
49. Poli M, Girelli D, Campostrini N, Maccarinelli F, Finazzi D, et al. (2011) Heparin: a potent inhibitor of hepcidin expression in vitro and in vivo. Blood 117: 997-1004.